CAG
53
12
TXN
35
7
MMC
37
-3
WY
33
2
V
58
2
BXP
38
4
SHW
33
2
BEN
36
4
MAC
53
5
GRMN
46
3
HIG
46
2
WDC
41
4
CSCO
58
-2
PRU
45
5
AMP
43
3
RF
47
4
MDLZ
26
2
MUR
31
-3
FITB
30
2
AES
49
3
CAG
53
12
TXN
35
7
MMC
37
-3
WY
33
2
V
58
2
BXP
38
4
SHW
33
2
BEN
36
4
MAC
53
5
GRMN
46
3
HIG
46
2
WDC
41
4
CSCO
58
-2
PRU
45
5
AMP
43
3
RF
47
4
MDLZ
26
2
MUR
31
-3
FITB
30
2
AES
49
3
Financhill
Back

Hansoh Pharmaceutical Group 10K Form

Sell
39

HNSPF
Hansoh Pharmaceutical Group

Last Price:
$2.10
Seasonality Move:
2.73%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive HNSPF News And Ratings

See the #1 stock for the next 7 days that we like better than HNSPF

HNSPF Financial Statistics

Sales & Book Value

Annual Sales: $1.4B
Cash Flow: $0
Price / Cash Flow: 21.99
Annual Sales: $0.65
Price / Book: 3.25

Profitability

EPS (TTM): 0.10560
Net Income (TTM): $655.2M
Gross Margin: $1.3B
Return on Equity: 18.18%
Return on Assets: 14.65%

Hansoh Pharmaceutical Group Earnings Forecast

Key Hansoh Pharmaceutical Group Financial Ratios

  • The Gross Profit Margin over the past 8 years for HNSPF is 89.80%.
  • The Selling, General & Administrative Expenses for HNSPF have been equal to 41.97% of Gross Profit Margin.
  • The Research & Development expenses have been 20.76% of Revenue.
  • The Interest Expense is 2.03% of Operating Income.
  • The Net Earning history of HNSPF is 32.44% of Total Revenues.
  • Per Share Earnings over the last 8 years have been positive in 5 years.

Hansoh Pharmaceutical Group Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: OTCM
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: HNSPF
Website: hspharm.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 7.98
Quick Ratio: 7.81

Price-to-Earnings

Trailing P/E Ratio: 28.57
Forward P/E Ratio: 0

HNSPF Technical Analysis vs Fundamental Analysis

Sell
39
Hansoh Pharmaceutical Group (HNSPF) is a Sell

Is Hansoh Pharmaceutical Group a Buy or a Sell?